Stephen Russell, president and CEO of Vyriad (Vyriad)
Regeneron-backed oncolytic virus startup scores modest Series B extension
Three years ago, Regeneron collaborated with tiny, Rochester, MN biotech Vyriad to kickstart a Phase II trial. That collaboration deal would combine Regeneron’s PD-1 drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.